Skip to content
DraconiticResearch
Search Sources API
201,642 studies31 sourcesUpdated 12 min ago
Peer-reviewedCC BY-NCJournal for immunotherapy of cancer

Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner.

  • Zhe Fu1
  • Victoria Jackson-Patel2
  • Kathryn Farrand1
  • Alisha R Dabb1
  • Xiaojing Lin2
  • Emily Liu2
  • Amir Ashoorzadeh2
  • Jeff B Smaill2
  • Ian F Hermans1
  • Adam V Patterson3
  1. 1Malaghan Institute of Medical Research, Wellington, New Zealand.
  2. 2Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand.
  3. 3Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand [email protected].
Read full textPDFDOICite

Related

  1. TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement
    F. Lynce, K. Shimada, C. Isaacs +18
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  2. A therapeutic vulnerability linking MNK1/2 inhibition and G1/S cyclin-dependent kinase blockade in triple-negative breast cancer
    Q. Deng, M. Amiri, A. Moshari +11
    bioRxivPreprintCC BYFull textOncologybioRxiv
  3. Moving Beyond the Plateau in Immune Checkpoint Inhibition-The Imperative of Early Referral and Precision Strategies.
    Razelle Kurzrock
    Journal of immunotherapy and precision oncologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  4. 418 B cell regulation of anti-PD-1 immune checkpoint inhibition
    Martin J Cannon, Richard A Connor, Lisa R Williams
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  5. Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis
    Ahmed Farid Gadelmawla, Ahmed A. Abo Elnaga, Abdullah Faisal Albukhari +10
    Future OncologyPeer-reviewedLicence not statedFull textClinical trials & evidence synthesisPMC

Cite

BibTeXRIS
BibTeX
@article{fu2026tarloxotinib,
  title = {{Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner.}},
  author = {Zhe Fu and Victoria Jackson-Patel and Kathryn Farrand and Alisha R Dabb and Xiaojing Lin and Emily Liu and Amir Ashoorzadeh and Jeff B Smaill and Ian F Hermans and Adam V Patterson},
  journal = {Journal for immunotherapy of cancer},
  year = {2026},
  month = oct,
  doi = {10.1136/jitc-2025-013057},
  url = {https://europepmc.org/article/MED/42906944},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner.
AU  - Zhe Fu
AU  - Victoria Jackson-Patel
AU  - Kathryn Farrand
AU  - Alisha R Dabb
AU  - Xiaojing Lin
AU  - Emily Liu
AU  - Amir Ashoorzadeh
AU  - Jeff B Smaill
AU  - Ian F Hermans
AU  - Adam V Patterson
PY  - 2026
DA  - 2026/10/21
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2025-013057
UR  - https://europepmc.org/article/MED/42906944
SN  - 2051-1426
ER  -